Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving Elranatamab

First published: 05/05/2026

Last updated: 05/05/2026

Study Planned

Administrative details

EU PAS number

EUPAS1000000853

Study ID

1000000853

DARWIN EU® study

No

Study countries

United States

Study status

Planned

Contact details

Study institution contact

Makiko Fukaya makiko.fukaya@pfizer.com

Study contact

makiko.fukaya@pfizer.com

Primary lead investigator

Chen Yong

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 31/07/2025

Actual: 31/07/2025

Study start date

Planned: 27/03/2026

Date of final study report

Planned: 01/04/2027

Study protocol

C1071052_PROTOCOL v1.0_16FEB2026_Redacted.pdf (2.31 MB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

No

Check completeness

No

Check stability

No

Check logical consistency

No

Data characterisation

Data characterisation conducted

No